Outlook Therapeutics Inc. (41O)
XFRA 
Summary
41O Chart
OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp
Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript
Oncobiologics Q3 Earnings Call Highlights
Oncobiologics NASDAQ: OTLK said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, or wet AMD, in the United States.
Outlook Therapeutics Inc. (41O) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Outlook Therapeutics Inc. ever had a stock split?
Outlook Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Robert Charles Jahr CEO | XFRA Exchange | 69012T305 CUSIP |
| US Country | 17 Employees | 18 Mar 2019 Last Dividend | 14 Mar 2024 Last Split | 13 May 2016 IPO Date |
Overview
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a strong focus on developing and commercializing monoclonal antibodies targeted at a variety of ophthalmic conditions. Originally known as Oncobiologics, Inc., the company underwent a name change to Outlook Therapeutics, Inc. in November 2018, marking a significant redirection of its operational focus. Established in 2010 and headquartered in Iselin, New Jersey, Outlook Therapeutics is dedicated to addressing the unmet medical needs in the field of ophthalmology, leveraging advanced scientific research and strategic collaborations. The company has entered into noteworthy collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd., underscoring its commitment to expanding its research capabilities and enhancing its product portfolio through strategic partnerships.
Products and Services
- ONS-5010
ONS-5010 stands as the lead product candidate of Outlook Therapeutics, representing a significant innovation in the treatment of ophthalmic diseases. It is an ophthalmic formulation of bevacizumab that is specifically designed for the treatment of wet age-related macular degeneration (AMD) along with other retinal diseases. Currently, ONS-5010 is in Phase-III clinical trials, demonstrating Outlook Therapeutics’ dedication to advancing its development through rigorous scientific evaluation. This product aims to offer a new therapeutic option for patients suffering from retinal diseases, potentially improving vision and quality of life for millions globally.
